BioSpace News Archive

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System

November 10, 2022
·
7 min read
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

Manufactured first batch of drug substance under cGMP conditions Analysis of challenge study data underway

November 10, 2022
·
8 min read
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the

November 10, 2022
·
10 min read
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants

Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & Expo

November 10, 2022
·
3 min read
Business

Reports: Neuro-Focused Faze Medicines to Shutter Operations

Third Rock-founded Faze Medicines appears to be shuttering operations, with several former employees signaling they are looking for new jobs.

November 10, 2022
·
2 min read
·
Tristan Manalac
Business

Amidst Restructuring, Ambrx Doses First Patient with Anti-CD70 ADC

An anti-CD70 antibody drug conjugate developed by Ambrx, Inc. has been administered to the first patient in a Phase I study in China. It marks the first ADC in active development that targets CD70.

November 10, 2022
·
3 min read
·
Alex Keown
Business

Movers & Shakers: Odyssey, Daiichi Sankyo, Atsena and More

While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.

November 10, 2022
·
6 min read
·
Alex Keown
Business

Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates

Valneva SE reported consolidated financial results for the first nine months of the year, ended September 30, 2022.

November 10, 2022
·
26 min read
Business

IRRAS AB publishes Interim Report for the period January to September 2022

IRRAS announced and completed a fully subscribed rights issue that raised MSEK 215 before deduction of costs related to the transaction.

November 10, 2022
·
4 min read
Business

Almirall’s Nine-month 2022 Results

Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results.

November 10, 2022
·
13 min read